Clearside biomedical's lead clinical program cls-ax in wet amd and suprachoroidal delivery platform highlighted at the 2025 wet amd & diabetic eye disease summit

- post-hoc analyses provide comparative data on rescue criteria and intervention-free rates for tyrosine kinase inhibitors (tkis) in wet amd development -

CLS Ratings Summary

CLS Quant Ranking